The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy

Eur Heart J. 2019 Aug 1;40(29):2441-2443. doi: 10.1093/eurheartj/ehz263.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aspirin*
  • Coronary Artery Bypass
  • Fibrinolytic Agents
  • Humans
  • Myocardial Infarction*
  • Ticagrelor

Substances

  • Fibrinolytic Agents
  • Ticagrelor
  • Aspirin